Business Wire

CLUE

17.11.2021 01:03:12 CET | Business Wire | Press release

Share
Clue, a SaaS Investigation and Intelligence Platform, Announces £5m Strategic Growth Investment From Frog Capital

Clue, a SaaS platform for managing investigations, today announced growth investment of £5 million from Frog Capital, a leading investor in European scale-up software. Demand for Clue has more than doubled over the last two years, driven by co-owners Clare Elford, CEO, and Thomas Drohan, CCO. From its roots in policing, the platform is now used across government, private and non-profit sectors to investigate cyber-crime, fraud, child protection, corruption, environmental crime, cheating in sports and much more. Clare and Thomas are joined on the board of directors by Nick Harber, CFO; Mike Reid, Senior Partner at Frog Capital; and Adam Hale, Chair of the ScaleUp Institute, as Chairman.

Clare Elford, CEO, said: “The world of intelligence and investigations is no longer constrained to policing, there is much wider application. Organisations are under growing scrutiny, finding themselves more susceptible to threats and with a much greater duty of care towards the vulnerable.

“Clue has productised decades of investigation expertise into a platform that empowers intelligence officers and investigation experts to achieve successful outcomes. So many of those dedicated to preventing harm and seeking justice have to deal with an overwhelming volume and complexity of data. Still reliant on legacy systems, or even spreadsheets, this is a sector primed for digital transformation.”

Thomas Drohan, CCO, said “With this investment, we will strengthen the capabilities of the platform with further AI and ML capability, automation, data insights and business intelligence, while continuing to support and build our user community. Frog have a formidable track record, with an impressive team who we are looking forward to working with to deploy the Scale-up Methodology and drive business growth and a solution to better serve the market.”

Mike Reid, at Frog Capital who joins Clue’s board said: “Across the industries that Clue serves there's a deep-rooted frustration at the lack of good enough tech to allow people to do their investigative work as efficiently and thoroughly as they need. For too long there's been a staggering underinvestment in how investigations are done, resulting in missed opportunities and slow outcomes for hardworking investigative teams and the people they serve.

“Clue's technology is genuinely delivering very significant clients a step change in how they manage and resolve incredibly complex and sensitive investigation cases. With Frog’s investment and experienced team of operators, Clue can accelerate their incredibly positive organisational and, critically, social impact in the key fields of policing, child welfare, financial crime amongst many others.”

Clue’s new Chairman, Adam Hale, said: “'I first met Clare and Thomas just before the pandemic and was really impressed with what they had built and the magnitude of customer problem that Clue solves. Since then, working with the ScaleUp Group, they have raised value-added SaaS growth investment from Frog Capital. I have known Frog for many years and am delighted to become part of their portfolio. I'm also really excited to work with Nick Harber again. I studied Computer Science in Bristol in the 80s and love coming back to a city set to support high growth organisations such as Clue.

“Now is the 'end of the beginning' for Clue and the start of the path to market leadership. From speaking to customers, I can hear how invaluable Clue is to them. There is so much opportunity and I'm thrilled to be part of it.”

About Clue
Clue is a cloud-based investigation case management and intelligence platform that enables organisations to prevent harm and secure justice by building intelligence and quickly progressing investigations in the face of evolving threats, increasing volumes of data, and the need for multi-agency collaboration.

About Frog Capital
Frog Capital is a specialist software Scale-Up Investor in high-growth European software companies and software-enabled businesses at the Scale-Up stage. Frog has a team of in-house operating partners who actively support their portfolio at executive level across the wide range of business challenges they face. Frog has combined over 20 years of experience to create its unique Scale-Up Methodology, which provides a framework defining the major elements of success through the Scale-Up phase.

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release

Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he

Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release

Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co

Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth

Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release

Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th

CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release

The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye